Literature DB >> 340319

Treatment of alcoholic hepatitis with encephalopathy. Comparison of prednisolone with caloric supplements.

H R Lesesne, E M Bozymski, H J Fallon.   

Abstract

A previous report from this institution demonstrated significant improvement of caloric intake and survival in patients with alcoholic hepatitis and hepatic encephalopathy given prednisolone when compared with placebo. The purpose of this study was to compare the effects of prednisolone with a regimen of 1600 calories per day without prednisolone. Fourteen patients with alcoholic hepatitis and encephalopathy were studied. All 7 on caloric supplementation and 2 of 7 given prednisolone died (p less than 0.01). These results suggest that prednisolone therapy reduces the mortality of those patients with alcoholic hepatitis and hepatic encephalopathy. This effect does not appear to be related to total caloric intake.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 340319

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  19 in total

1.  Corticosteroids and pentoxifylline for the treatment of alcoholic hepatitis: Current status.

Authors:  Ashwani K Singal; Ishmeet Walia; Anjna Singal; Roger D Soloway
Journal:  World J Hepatol       Date:  2011-08-27

Review 2.  Interaction of alcohol with other drugs and nutrients. Implication for the therapy of alcoholic liver disease.

Authors:  C S Lieber
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 3.  Corticosteroids Versus Pentoxifylline for Severe Alcoholic Hepatitis: A Sequential Analysis of Randomized Controlled Trials.

Authors:  Basile Njei; Albert Do; Thomas R McCarty; Brett E Fortune
Journal:  J Clin Gastroenterol       Date:  2016 Nov/Dec       Impact factor: 3.062

4.  An Open-Label, Dose-Escalation Study to Assess the Safety and Efficacy of IL-22 Agonist F-652 in Patients With Alcohol-associated Hepatitis.

Authors:  Juan P Arab; Tejasav S Sehrawat; Douglas A Simonetto; Vikas K Verma; Dechun Feng; Tom Tang; Kevin Dreyer; Xiaoqiang Yan; William L Daley; Arun Sanyal; Naga Chalasani; Svetlana Radaeva; Liu Yang; Hugo Vargas; Mauricio Ibacache; Bin Gao; Gregory J Gores; Harmeet Malhi; Patrick S Kamath; Vijay H Shah
Journal:  Hepatology       Date:  2020-04-27       Impact factor: 17.425

5.  Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study.

Authors:  B L Blitzer; M G Mutchnick; P H Joshi; M M Phillips; J M Fessel; H O Conn
Journal:  Am J Dig Dis       Date:  1977-06

Review 6.  Corticosteroids in liver disease: possible mechanisms of action, pharmacology, and rational use.

Authors:  A R Tanner; L W Powell
Journal:  Gut       Date:  1979-12       Impact factor: 23.059

Review 7.  Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease): an attempted network meta-analysis.

Authors:  Elena Buzzetti; Maria Kalafateli; Douglas Thorburn; Brian R Davidson; Maja Thiele; Lise Lotte Gluud; Cinzia Del Giovane; Gro Askgaard; Aleksander Krag; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-03-31

Review 8.  Advances in alcoholic liver disease: An update on alcoholic hepatitis.

Authors:  Randy Liang; Andy Liu; Ryan B Perumpail; Robert J Wong; Aijaz Ahmed
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

9.  Management of alcoholic hepatitis: Current concepts.

Authors:  Hetal A Karsan; Samir Parekh
Journal:  World J Hepatol       Date:  2012-12-27

Review 10.  Alcoholic hepatitis: a comprehensive review of pathogenesis and treatment.

Authors:  Maneerat Chayanupatkul; Suthat Liangpunsakul
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.